Vontobel Holding Ltd. Sells 92,362 Shares of IQVIA Holdings Inc. $IQV

Vontobel Holding Ltd. lowered its stake in IQVIA Holdings Inc. (NYSE:IQV) by 16.8% during the 4th quarter, HoldingsChannel.com reports. The fund owned 458,068 shares of the medical research company’s stock after selling 92,362 shares during the quarter. Vontobel Holding Ltd.’s holdings in IQVIA were worth $103,253,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the business. Claret Asset Management Corp increased its holdings in shares of IQVIA by 1.1% in the 3rd quarter. Claret Asset Management Corp now owns 4,527 shares of the medical research company’s stock valued at $860,000 after acquiring an additional 49 shares during the last quarter. Leonard Rickey Investment Advisors P.L.L.C. increased its holdings in shares of IQVIA by 3.3% in the 4th quarter. Leonard Rickey Investment Advisors P.L.L.C. now owns 1,814 shares of the medical research company’s stock valued at $409,000 after acquiring an additional 58 shares during the last quarter. Quadrant Capital Group LLC increased its holdings in shares of IQVIA by 1.3% in the 4th quarter. Quadrant Capital Group LLC now owns 4,792 shares of the medical research company’s stock valued at $1,080,000 after acquiring an additional 60 shares during the last quarter. Private Advisor Group LLC increased its holdings in shares of IQVIA by 1.0% in the 3rd quarter. Private Advisor Group LLC now owns 6,122 shares of the medical research company’s stock valued at $1,163,000 after acquiring an additional 63 shares during the last quarter. Finally, Brookstone Capital Management grew its stake in IQVIA by 2.2% during the 4th quarter. Brookstone Capital Management now owns 2,931 shares of the medical research company’s stock worth $661,000 after buying an additional 63 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Trading Up 0.0%

Shares of IQV stock opened at $181.10 on Friday. The business’s 50 day moving average is $173.56 and its two-hundred day moving average is $193.68. IQVIA Holdings Inc. has a twelve month low of $153.01 and a twelve month high of $247.04. The company has a market capitalization of $30.23 billion, a P/E ratio of 22.44, a price-to-earnings-growth ratio of 1.55 and a beta of 1.21. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The company had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. During the same period last year, the business posted $2.70 EPS. The company’s revenue was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities analysts forecast that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA announced that its board has authorized a share buyback plan on Thursday, May 7th that allows the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization allows the medical research company to repurchase up to 6.8% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its shares are undervalued.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on IQV. Wall Street Zen downgraded IQVIA from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Morgan Stanley set a $225.00 price target on IQVIA in a research note on Thursday, May 7th. Barclays upgraded IQVIA from an “equal weight” rating to an “overweight” rating and set a $210.00 price target on the stock in a research note on Friday, March 6th. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and raised their price target for the stock from $174.00 to $213.00 in a research note on Monday, March 9th. Finally, Royal Bank Of Canada began coverage on IQVIA in a research note on Tuesday, March 3rd. They set an “outperform” rating and a $221.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, IQVIA presently has a consensus rating of “Buy” and an average target price of $224.13.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.